These data underscore the promise of next-generation therapies and the potential for icotrokinra to offer adolescents with moderate to severe plaque psoriasis the unique combination of a favorable ...

To find answers to these questions, Empa researchers are working together with clinical partners on a model of human skin.

Icotrokinra achieved 75% complete skin clearance in adolescents with moderate to severe plaque psoriasis by week 24, indicating significant efficacy. The ICONIC-LEAD trial is the first to evaluate ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin by week 24. Results from the Phase III ...

"A primary treatment goal for people living with psoriasis is durable, high rates of complete skin clearance ... adverse reactions in plaque psoriasis and hidradenitis suppurativa include upper ...

In moderate to severe plaque psoriasis, two highly selective ... that drugs in this class might rival biologics. In one, a 75% skin clearance on the Psoriasis Area Severity Index (PASI) was ...

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis ... score of 0/1 (clear or almost clear skin) with at least a 2-grade improvement ...